Werewolf Therapeutics, Inc. Common Stock
HOWLWerewolf Therapeutics, Inc. (HOWL) is a biotechnology company focused on developing targeted immunotherapies for cancer. The company aims to create novel therapies that stimulate the immune system to fight tumors more effectively, utilizing innovative approaches in cytokine and immunomodulatory drug design.
Company News
Werewolf Therapeutics announced it is exploring strategic alternatives to maximize stockholder value, including potential sale, merger, asset sale, or licensing arrangements. The company reported improved financial metrics for 2025 with reduced R&D and G&A expenses, lower net losses compared to 2024, and cash reserves of $57.1 million expected to...
Multiple major M&A activities and bankruptcies dominate the market: Funko surges 25% after investor urges sale exploration; Caesars Entertainment weighs takeover offers including from billionaire Tilman Fertitta; Netflix loses Warner Bros. bidding war to Paramount Skydance's $111B offer; GSK acquires 35Pharma for $950M; and iPic Theaters files fo...
Werewolf Therapeutics will present three scientific posters at the Society for Immunotherapy of Cancer's 40th Annual Meeting, highlighting research on conditionally activated immune therapeutics for cancer treatment.
Werewolf Therapeutics reported Q2 2025 results with no revenue, continued investment in cancer immunotherapy research, and focus on advancing clinical trials for WTX-124 and WTX-330 drug candidates.
Werewolf Therapeutics provided updates on its clinical trials, including progress with WTX-124 and WTX-330, and announced the development of its proprietary INDUCER T cell engager molecules. The company also reported its financial results for the first quarter of 2025, with a cash runway into the fourth quarter of 2026.
